Study of Nicotine for Pain Associated With Chemotherapy-Induced Peripheral Neuropathy

Inclusion Criteria: * Clinically diagnosed peripheral sensory neuropathy defined as: * Greater than Grade 1 peripheral sensory neuropathy using the CTCAE v5.0 grading scale * Grade 1 Asymptomatic * Grade 2 Moderate symptoms; limiting instrumental activities of daily living (ADL) * Grade 3 Severe symptoms; limiting self-care ADL * Grade 4 Life-threatening consequences; urgent intervention indicated * Have a baseline chemotherapy-induced peripheral neuropathy (CIPN) patient reported outcome (PRO) total sensory score ≥ 24.3 on a 19 to 76 scale using the European Organization for Research and Treatment of Cancer Quality of Life-CIPN20 Questionnaire (EORTC QLQ-CIPN-20) * Have a CIPN-related neuropathic pain score ≥ 4 on a 0 to 10 scale using the Brief Pain Inventory-Short Form (BPI-SF) item 5 * Will not have used any nicotine or tobacco products (eg, cigarettes, electronic cigarettes, smokeless tobacco, or other nicotine replacement therapies) within 14 days prior to study treatment start date * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * Not currently receiving any chemotherapy * Have previously received platinum- and/or taxane-based chemotherapy treatments and have persistent pain at least 3 months after completion of treatments. * Willing and able to comply with study procedures and visit schedule. * Willing to abstain from all tobacco/nicotine product use during study treatment and 30-day follow-up period. * Ability to self-apply or h…